Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge.

Alzheimer's disease cross-comparison decision-analytic modeling dementia economic evaluation model validation

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
05 2023
Historique:
revised: 14 04 2022
received: 19 07 2021
accepted: 02 09 2022
medline: 15 5 2023
pubmed: 27 10 2022
entrez: 26 10 2022
Statut: ppublish

Résumé

The credibility of model-based economic evaluations of Alzheimer's disease (AD) interventions is central to appropriate decision-making in a policy context. We report on the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge. Two common benchmark scenarios, for the hypothetical treatment of AD mild cognitive impairment (MCI) and mild dementia, were developed jointly by 29 participants. Model outcomes were summarized, and cross-comparisons were discussed during a structured workshop. A broad concordance was established among participants. Mean 10-year restricted survival and time in MCI in the control group ranged across 10 MCI models from 6.7 to 9.5 years and 3.4 to 5.6 years, respectively; and across 4 mild dementia models from 5.4 to 7.9 years (survival) and 1.5 to 4.2 years (mild dementia). The model comparison increased our understanding of methods, data used, and disease progression. We established a collaboration framework to assess cost-effectiveness outcomes, an important step toward transparent and credible AD models.

Identifiants

pubmed: 36284403
doi: 10.1002/alz.12811
pmc: PMC10126209
mid: NIHMS1852410
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1800-1820

Subventions

Organisme : NIA NIH HHS
ID : R01 AG060871
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066589
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG069771
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG024968
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062277
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG059623
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG060165
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG024904
Pays : United States

Informations de copyright

© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

Dement Geriatr Cogn Disord. 2010;29(1):61-7
pubmed: 20110702
Curr Alzheimer Res. 2013 Feb;10(2):207-16
pubmed: 23036018
Health Econ Rev. 2018 Mar 26;8(1):8
pubmed: 29582186
BMC Health Serv Res. 2014 Jan 03;14:2
pubmed: 24383766
Value Health. 2018 Jun;21(6):724-731
pubmed: 29909878
Lancet. 2016 Jan 23;387(10016):367-375
pubmed: 26549466
J Alzheimers Dis. 2020;75(3):891-902
pubmed: 32390617
Int J Chron Obstruct Pulmon Dis. 2017 Nov 01;12:3183-3194
pubmed: 29138546
Expert Rev Pharmacoecon Outcomes Res. 2020 Dec;20(6):563-570
pubmed: 32951480
Int Psychogeriatr. 2018 Nov;30(11):1593-1605
pubmed: 30475198
Diabetes Care. 2007 Jun;30(6):1638-46
pubmed: 17526823
Eur J Health Econ. 2019 Apr;20(3):343-355
pubmed: 30178148
Eur J Epidemiol. 2022 Aug;37(8):807-814
pubmed: 35731313
Alzheimers Dement (N Y). 2018 Feb 16;4:76-88
pubmed: 29687076
Diabetes Res Clin Pract. 2000 Nov;50 Suppl 3:S57-64
pubmed: 11080563
J Gerontol B Psychol Sci Soc Sci. 2018 Apr 16;73(suppl_1):S38-S47
pubmed: 29669100
J Gerontol B Psychol Sci Soc Sci. 2013 May;68(3):374-90
pubmed: 23033357
Value Health. 2013 Jun;16(4):670-85
pubmed: 23796302
Alzheimers Res Ther. 2020 Dec 11;12(1):166
pubmed: 33308302
Alzheimers Dement. 2017 Mar;13(3):312-321
pubmed: 28063281
J Health Serv Res Policy. 2012 Jan;17(1):44-52
pubmed: 21954237
Value Health. 2017 Mar;20(3):397-403
pubmed: 28292484
Pharmacoeconomics. 2017 Jan;35(1):125-128
pubmed: 27928759
Alzheimers Dement. 2019 Oct;15(10):1309-1321
pubmed: 31402324
Brain. 2015 May;138(Pt 5):1327-38
pubmed: 25693589
Value Health. 2012 Sep-Oct;15(6):843-50
pubmed: 22999134
Pharmacoeconomics. 2016 Jul;34(7):681-707
pubmed: 26899832
J Alzheimers Dis. 2021;83(2):591-608
pubmed: 34334392
Curr Alzheimer Res. 2018;15(8):777-788
pubmed: 29357799
Value Health. 2020 Sep;23(9):1163-1170
pubmed: 32940234
J Am Geriatr Soc. 2017 Oct;65(10):2169-2175
pubmed: 28815557
BMC Med. 2019 Aug 19;17(1):163
pubmed: 31422772
Alzheimers Dement (N Y). 2022 Oct 26;8(1):e12360
pubmed: 36313968
J Health Serv Res Policy. 2007 Jan;12(1):11-7
pubmed: 17244392
Med Decis Making. 2020 May;40(4):474-482
pubmed: 32486894
Value Health. 2014 Jul;17(5):525-36
pubmed: 25128045
Alzheimers Dement. 2018 Apr;14(4):462-472
pubmed: 29396108

Auteurs

Ron L H Handels (RLH)

Maastricht University, Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neurosciences, Maastricht, The Netherlands.
Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.

Colin Green (C)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.
Health Economics Group, University of Exeter College of Medicine and Health, University of Exeter, Exeter, UK.

Anders Gustavsson (A)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.
Quantify Research, Hantverkargatan 8, Stockholm, Sweden.

William L Herring (WL)

RTI Health Solutions, Research Triangle Park, North Carolina, USA.

Bengt Winblad (B)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.

Anders Wimo (A)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.

Anders Sköldunger (A)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.

Andreas Karlsson (A)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden.

Robert Anderson (R)

Care Policy Evaluation Centre, London School of Economics, London, UK.

Mark Belger (M)

Eli Lilly and Company (UK), Bracknell, UK.

Chiara Brück (C)

Erasmus MC University Medical Center, Department of Public Health, Rotterdam, The Netherlands.

Robert Espinosa (R)

Medicus Economics LLC, Boston, Massachusetts, USA.

Jakub P Hlávka (JP)

University of Southern California, Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, California, USA.

Eric Jutkowitz (E)

Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA.
Providence Veterans Affairs (VA) Medical Center, Center of Innovation in Long Term Services and Supports, Providence, Rhode Island, USA.

Pei-Jung Lin (PJ)

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.

Mauricio Lopez Mendez (ML)

Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA.

Javier Mar (J)

Osakidetza Basque Health Service, Debagoiena Integrated Health Organisation, Research Unit, Arrasate-Mondragón, Spain.
Biodonostia Health Research Institute, Donostia-San Sebastián, Spain.

Peter Shewmaker (P)

Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA.

Eldon Spackman (E)

University of Calgary, Department of Community Health Sciences, Calgary, Canada.
O'Brien Institute of Public Health, Alberta, Canada.

Ali Tafazzoli (A)

Evidera, Bethesda, Maryland, USA.

Bryan Tysinger (B)

University of Southern California, Leonard D. Schaeffer Center for Health Policy & Economics, Los Angeles, California, USA.

Linus Jönsson (L)

Karolinska Institutet, Department for Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Solna, Sweden.
H. Lundbeck A/S, Valby, Denmark.
Maastricht University, Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neurosciences, Maastricht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH